Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough data to answer this question. That’s why the GENAYA project was launched in 2022. Through GENAYA, we are analyzing the tumor DNA of a total of 1,000 young cancer patients. As of July 2025, we’ve completed our 500th analysis.
With patient consent, we store the results in a large database that also contains data from over 7,000 other patients. This allows researchers worldwide to compare the data and investigate whether—and how—the DNA of cancer in young people differs from that in older adults, and whether this could lead to more targeted treatments specifically for young patients.
Funding
This project is made possible through funding from the Dutch Cancer Society (KWF Kankerbestrijding) and Fight Cancer Foundation. Illumina is also contributing to the project. Thanks to their support, more research can be conducted, and young cancer patients can receive comprehensive DNA analysis to determine whether there are any leads for targeted (clinical trial) treatments.
GENAYA Project
The GENAYA project (a national database of GENome data of Adolescent and Young Adult cancers) builds on the previously funded COMPRAYA infrastructure, which was also supported by KWF. For GENAYA, the Hartwig Medical Foundation performs diagnostic DNA analyses using whole genome sequencing.
Participating Hospitals
Currently, 37 hospitals are participating in the GENAYA project. This means they can enroll patients who meet the criteria to take part in the study.
More information: www.GENAYA.nl
You read an article in the category Personalized treatment. You may also be interested in GENAYA project, Hartwig Medical Database, Learning healthcare system, Participating hospitals, Research or Whole genome sequencing.All news
Also read
Whole genome sequencing: the future of molecular diagnostics in gynecological cancer?
To mark Gynecological Oncology Awareness Month, we spoke with oncologist Eelke Gort about the role of molecular diagnostics in these …
Clinical Trials Day and the importance of structurally recording treatment outcomes
Today, on Clinical Trials Day (May 20), we reflect on the importance of clinical research. For Hartwig, it’s a opportunity …
GenomeWeb: ‘Dutch Team Looks to Drug Repurposing to Improve Patient Outcomes, Lower Costs’
The project is an attempt to address the rising healthcare costs associated with new cancer drugs and to identify biomarkers …
Cancer is caused by DNA mutations. There are an increasing number of drugs available that act on specific errors in the DNA of an individual patient’s tumor. A drug that doesn’t fit, like a key in a lock, will not work, while the risk of side effects remains.